| 1.56 Data as of Jun 18 |  0.00 / 0.00%Today’s Change | 0.81 Today|||52-Week Range 1.84 | +14.71% Year-to-Date |
| SECTOR Health Services | INDUSTRY Services to the Health Industry | MARKET CAP $12.0M |
Company Description
Bioanalytical Systems, Inc. operates as a pharmaceutical development company which provides drug discovery and development services. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The company operates through two business segments: Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. The Research Products segment designs, develops, manufactures, and markets vivo sampling systems and accessories, physiology monitoring tools, liquid chromatography, and electrochemistry instruments platforms. Bioanalytical Systems was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Employees
Shareholders
| Individual stakeholders | 23.99% |
| Mutual fund holders | 2.14% |
| Other institutional | 1.97% |
Top Executives
| Jacqueline M. Lemke, CPA | President, Chief Executive Officer, CFO & Director |
| Scott Babbitt | Manager-Midwest Business Development |
| John P. Devine, Jr. | Vice President-Non-Clinical Services |
| Philip A. Downing | Senior Director-Preclinical Services |
| Peter T. Kissinger, PhD | Chairman-Emeritus |
.
